Toll Free: 1-888-928-9744

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Pipeline Review, H1 2016

Published: May 31, 2016 | Pages: 38 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Pipeline Review, H1 2016', provides in depth analysis on C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) targeted pipeline therapeutics. 

The report provides comprehensive information on the C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1)
- The report reviews C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) Overview 6 Therapeutics Development 7 C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Products under Development by Stage of Development 7 C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Products under Development by Therapy Area 8 C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Products under Development by Indication 9 C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Products under Development by Companies 12 C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 17 C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Companies Involved in Therapeutics Development 18 Bristol-Myers Squibb Company 18 ChemoCentryx, Inc. 19 Ligand Pharmaceuticals, Inc. 20 C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Drug Profiles 21 BMS-457 - Drug Profile 21 Product Description 21 Mechanism Of Action 21 R&D Progress 21 CCX-354 - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 CCX-9588 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 Drug to Antagonize CCR1 for Oncology - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 PS-031291 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 Small Molecule to Antagonize CCR1 for Undisclosed Indication - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 Small Molecules to Antagonize CCR and CXCR for Oncology and Autoimmune Disease - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Dormant Projects 29 C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Discontinued Products 30 C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Featured News & Press Releases 31 Apr 18, 2016: ChemoCentryx Announces Immuno-Oncology Data Presentation at the American Association for Cancer Research (AACR) Annual Meeting 31 Jun 08, 2012: ChemoCentryx Announces Peer-Reviewed Publication Of Positive Phase II Clinical Data With CCX354 In Patients With Rheumatoid Arthritis 31 Nov 08, 2011: ChemoCentryx Reports Clinical Efficacy For CCX354 In Phase II Study In Patients With Rheumatoid Arthritis 32 Nov 09, 2010: ChemoCentryx Reports Favorable Phase I Results For CCX354 In Rheumatoid Arthritis At Annual American College Of Rheumatology Meeting 33 Jun 17, 2010: ChemoCentryx Reports Positive Phase I Study Results For CCX354 34 Dec 16, 2009: ChemoCentryx Initiates Phase 2 Clinical Trial Of CCX354 For The Treatment Of Rheumatoid Arthritis 35 May 13, 2008: ChemoCentryx Initiates Clinical Trial Of CCX354 For The Treatment Of Inflammatory Disease 35 Feb 11, 2008: Pharmacopeia Nominates PS031291 For Development 36 Appendix 37 Methodology 37 Coverage 37 Secondary Research 37 Primary Research 37 Expert Panel Validation 37 Contact Us 37 Disclaimer 38
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Products under Development by Companies, H1 2016 13 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Stage and Mechanism of Action, H1 2016 15 Number of Products by Stage and Route of Administration, H1 2016 16 Number of Products by Stage and Molecule Type, H1 2016 17 Pipeline by Bristol-Myers Squibb Company, H1 2016 18 Pipeline by ChemoCentryx, Inc., H1 2016 19 Pipeline by Ligand Pharmaceuticals, Inc., H1 2016 20 Dormant Projects, H1 2016 29 Discontinued Products, H1 2016 30


List of Figures
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Top 10 Indication, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 11 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Stage and Mechanism of Actions, H1 2016 15 Number of Products by Stage and Routes of Administration, H1 2016 16 Number of Products by Stage and Molecule Type, H1 2016 17

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global polymethyl methacrylate (PMMA) market size is likely to be valued at USD 11.65 billion by 2022; as per a new research report by Radiant Insights, Inc. Increasing spending on advertising & marketing for building strong brand equity and product

Read More...

Global automotive relay market is anticipated to reach USD 12 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising need for high-frequency signals in automotive industry is expected to drive demand. These relays enhance driv

Read More...

Global air traffic control equipment market is projected to reach USD 4.2 billion by 2020, as per a new research report by Radiant Insights, Inc. Mounting price sensitivity among customers with introduction of low fare airlines is expected to drive t

Read More...

Global fingerprint access control systems market size is estimated to reach USD 4.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Growing safety and security concerns of individual as well as organization is projected to dri

Read More...

Global integrated systems market is projected to reach USD 24 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to re-evaluate data center infrastructure is expected to boost the demand. Change in trend from main

Read More...
Choose License Type
Single User - US $3500
Multi User - US $7000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify